Difference between revisions of "Alvocidib (Flavopiridol)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Chronic lymphocytic leukemia (CLL) and Small lymphocytic lymphoma (SLL)" to "Chronic lymphocytic leukemia (CLL/SLL)") |
m |
||
| Line 1: | Line 1: | ||
==Mechanism of action== | ==Mechanism of action== | ||
| − | + | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=42068 NCI Drug Dictionary]: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis. | |
<br>Route: PO | <br>Route: PO | ||
| Line 10: | Line 10: | ||
*4/13/2007: Granted orphan status for treatment of [[Chronic lymphocytic leukemia (CLL/SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]] or prolymphocytic leukemia arising from CLL. | *4/13/2007: Granted orphan status for treatment of [[Chronic lymphocytic leukemia (CLL/SLL) | B-cell chronic lymphocytic leukemia (B-CLL)]] or prolymphocytic leukemia arising from CLL. | ||
*4/23/2014: Granted orphan designation for the treatment of patients with [[Acute myeloid leukemia | acute myeloid leukemia (AML)]] | *4/23/2014: Granted orphan designation for the treatment of patients with [[Acute myeloid leukemia | acute myeloid leukemia (AML)]] | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' HMR 1275, L-868275 | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| + | |||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:CDK inhibitors]] | [[Category:CDK inhibitors]] | ||
| Line 20: | Line 23: | ||
[[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] | [[Category:Chronic lymphocytic leukemia (CLL/SLL) medications]] | ||
| − | |||
[[Category:Orphan drug]] | [[Category:Orphan drug]] | ||
| + | [[Category:Investigational]] | ||
Revision as of 18:28, 29 October 2017
Mechanism of action
From the NCI Drug Dictionary: A synthetic N-methylpiperidinyl chlorophenyl flavone compound. As an inhibitor of cyclin-dependent kinase, alvocidib induces cell cycle arrest by preventing phosphorylation of cyclin-dependent kinases (CDKs) and by down-regulating cyclin D1 and D3 expression, resulting in G1 cell cycle arrest and apoptosis.
Route: PO
Diseases for which it is used
History of changes in FDA indication
- 4/13/2007: Granted orphan status for treatment of B-cell chronic lymphocytic leukemia (B-CLL) or prolymphocytic leukemia arising from CLL.
- 4/23/2014: Granted orphan designation for the treatment of patients with acute myeloid leukemia (AML)
Also known as
- Code names: HMR 1275, L-868275